Jaguar Health, Inc. Uncategorized Contracts & Agreements
56 Contracts & Agreements
- Fourth ATM Amendment, dated November 13, 2024, to ATM Agreement by and among Jaguar Health, Inc., Ladenburg Thalmann & Co. Inc. and Lucid Capital Markets, LLC (Filed With SEC on November 13, 2024)
- Third ATM Amendment, dated July 17, 2024, to ATM Agreement by and among Jaguar Health, Inc., Ladenburg Thalmann & Co. Inc. and Lucid Capital Markets, LLC (Filed With SEC on July 18, 2024)
- Second Amendment to the At the Market Offering Agreement, dated May 23, 2024, by and between Jaguar Health, Inc. and Ladenburg Thalmann & Co. Inc (Filed With SEC on May 23, 2024)
- Global Amendment No. 2, dated September 29, 2023, by and between Jaguar Health, Inc. and Streeterville Capital, LLC (Filed With SEC on October 5, 2023)
- Global Amendment, dated September 29, 2023, by and between Jaguar Health, Inc. and Streeterville Capital, LLC (Filed With SEC on October 5, 2023)
- Global Amendment No. 2, dated September 29, 2023, by and between Jaguar Health, Inc. and Uptown Capital, LLC (Filed With SEC on October 5, 2023)
- Global Amendment No. 2, dated September 29, 2023, by and between Jaguar Health, Inc. and Iliad Research and Trading, L.P (Filed With SEC on October 5, 2023)
- First Amendment to the Standstill Agreement, dated June 28, 2023, by and among Jaguar Health, Inc., Napo Pharmaceuticals, Inc., Iliad Research and Trading, L.P., Uptown Capital,... (Filed With SEC on July 3, 2023)
- Second Amendment to the Jaguar Health, Inc. New Employee Inducement Award Plan (Filed With SEC on May 19, 2023)
- Standstill Agreement (Filed With SEC on May 9, 2023)
- Global Amendment, dated October 17, 2022, by and among Jaguar Health, Inc., Napo Pharmaceuticals, Inc. and Streeterville Capital, LLC (Filed With SEC on October 21, 2022)
- Royalty Interest, dated August 24, 2022, by and between Jaguar Health, Inc. and Streeterville Capital, LLC (Filed With SEC on August 30, 2022)
- First Amendment to the Jaguar Health, Inc. New Employee Inducement Award Plan (Filed With SEC on April 15, 2022)
- Global Amendment, dated April 14, 2022, by and among Jaguar Health, Inc., Napo Pharmaceuticals, Inc. and Streeterville Capital, LLC (Filed With SEC on April 15, 2022)
- Global Amendment, dated April 14, 2022, by and between Jaguar Health, Inc. and Streeterville Capital, LLC (Filed With SEC on April 15, 2022)
- Global Amendment, dated April 14, 2022, by and between Jaguar Health, Inc. and Uptown Capital, LLC (Filed With SEC on April 15, 2022)
- Global Amendment, dated April 14, 2022, by and between Jaguar Health, Inc. and Iliad Research and Trading, L.P (Filed With SEC on April 15, 2022)
- First Amendment to the At the Market Offering Agreement, dated February 2, 2022, by and between Jaguar Health, Inc. and Ladenburg Thalmann & Co. Inc (Filed With SEC on February 2, 2022)
- At The Market Offering Agreement, dated December 10, 2021, by and between Jaguar Health, Inc. and Ladenburg Thalmann & Co. Inc (Filed With SEC on December 10, 2021)
- Royalty Interest, dated March 8, 2021, by and between Jaguar Health, Inc. and Streeterville Capital, LLC (Filed With SEC on March 11, 2021)
- Royalty Interest, dated December 22, 2020, by and between Jaguar Health, Inc. and Irving Park Capital, LLC (Filed With SEC on December 29, 2020)
- Royalty Interest, dated October 8, 2020, by and between Jaguar Health, Inc. and Iliad Research and Trading, L.P (Filed With SEC on October 9, 2020)
- At The Market Offering Agreement, dated October 5, 2020, by and between Jaguar Health, Inc. and Ladenburg Thalmann & Co. Inc (Filed With SEC on October 5, 2020)
- Global Amendment, dated September 1, 2020, by and among Jaguar Health, Inc., Napo Pharmaceuticals, Inc. and Chicago Venture Partners, L.P (Filed With SEC on September 2, 2020)
- Jaguar Health, Inc. New Employee Inducement Award Plan (Filed With SEC on June 19, 2020)
- Form of Inducement Letter for Bridge Warrants (Filed With SEC on May 22, 2020)
- Form of Inducement Letter for Original Warrants (Filed With SEC on May 22, 2020)
- Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1945, as amended (Filed With SEC on April 3, 2020)
- Leak-Out Agreement, dated March 24, 2020, by and between Jaguar Health, Inc. and the Holder named therein (Filed With SEC on March 26, 2020)
- Royalty Interest, dated March 4, 2020, by and between Jaguar Health, Inc. and Iliad Research and Trading, L.P (Filed With SEC on March 6, 2020)
- Lock-Up Agreement, dated December 23, 2019, by and between Jaguar Health, Inc. and Oasis Capital, LLC (Filed With SEC on December 26, 2019)
- Promotion Letter, dated September 6, 2019 (Filed With SEC on September 9, 2019)
- Form of Leak-out Agreement (Filed With SEC on July 18, 2019)
- Form of Amendment Agreement (Filed With SEC on July 5, 2019)
- Standstill Agreement, dated October 1, 2018, by and between Jaguar Health, Inc. and Chicago Venture Partners, L.P (Filed With SEC on October 5, 2018)
- Co-Promotion Agreement, dated June 28, 2018, by and between Napo Pharmaceuticals, Inc. and RedHill Biopharma, Inc (Filed With SEC on August 13, 2018)
- Offer Letter, dated May 25, 2018 (Filed With SEC on June 11, 2018)
- Offer Letter, dated May 25, 2018 (Filed With SEC on May 29, 2018)
- Consent and Payoff Agreement, dated February 27, 2018, by and between Napo Pharmaceuticals, Inc. and the purchasers named therein (Filed With SEC on February 28, 2018)
- Letter Agreement, dated October 25, 2017, by and between Jaguar Health, Inc. and Maxim Group LLC (Filed With SEC on October 26, 2017)
